We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The growth in Remodulin revenues resulted from an increase in U.S. Remodulin revenues and, to a lesser extent, an increase in international Remodulin revenues, driven, in both cases, by an ...
Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a prefilled syringe version of Vyvgart—also known as efgartigimod ...